Generic versions of Teva's multi-billion-dollar per year multiple sclerosis drug Copaxone (glatiramer) have arrived, but a closer look at which competitor might win the coveted 180-day exclusivity ...

Teva Pharmaceutical must face a lawsuit claiming it used unlawful methods to block generic competition for its multiple ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

Teva Pharmaceuticals Industries Ltd. dodged some claims and will continue to litigate others in multidistrict litigation brought by drug wholesalers and retailers, as well as a suit brought by a rival ...

Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...

Viatris likely just lost one of its top product debuts for 2024, thanks to an FDA rejection of its partner Mapi Pharma’s application for a new version of Teva’s multiple sclerosis (MS) drug Copaxone.

TAINAN, Jan. 5, 2026 /PRNewswire/ -- ScinoPharm Taiwan (TWSE: 1789) today announced a landmark achievement in the global pharmaceutical landscape, securing U.S. Food and Drug Administration (FDA) ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

Glatiramer acetate injection is a treatment for multiple sclerosis. ScinoPharm Taiwan pointed out that since its approval in 1996, glatiramer acetate has been recognized as one of the most challenging ...

San Antonio’s H-E-B and other major retailers have teamed up to wage legal battles on both coasts against pharmaceutical companies for allegedly monopolizing the market for certain prescription drugs.

Chinese GPU and AI chip makers captured nearly ‌41% of China's AI accelerator server market last year, eroding Nvidia's once-dominant position in one of its most important overseas markets, according ...